Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT03520686

Public ClinicalTrials.gov record NCT03520686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 8:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT03520686
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
ImmunityBio, Inc.
Industry
Enrollment
102 participants

Conditions and interventions

Interventions

  • Carboplatin and nab-paclitaxel plus atezolizumab. Drug
  • Carboplatin and paclitaxel plus atezolizumab and bevacizumab. Drug
  • Cisplatin/carboplatin and pemetrexed plus atezolizumab. Drug
  • Cisplatin/carboplatin and pemetrexed plus pembrolizumab. Drug
  • NAI + Nivolumab + Ipilimumab Drug
  • NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel Drug
  • NAI + Pembrolizumab Drug
  • NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel Drug
  • Pembrolizumab Drug
  • Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 17, 2018
Primary completion
Oct 12, 2025
Completion
Oct 12, 2025
Last update posted
Apr 14, 2026

2018 – 2025

United States locations

U.S. sites
31
U.S. states
18
U.S. cities
31
Facility City State ZIP Site status
Alaska Urological Institute - Alaska Clinical Research Center Anchorage Alaska 99503
Genesis Cancer Center Hot Springs Arkansas 71913
Chan Soon-Shiong Institute for Medicine El Segundo California 90245
Adventist Health Glendale Glendale California 92106
MemorialCare Health System Long Beach California 90806
Adventist Health White Memorial Los Angeles California 90033
Hoag Memorial Hospital Newport Beach California 92663
Desert Hematology Oncology Medical Group Rancho Mirage California 92270
Memorial Healthcare Hollywood Florida 33021
Baptist Health South Florida - Miami Cancer Institute Miami Florida 33176
Healthcare Research Network Tinley Park Illinois 60487
Baptist Health - Lexington Lexington Kentucky 40503
Baptist Health Louisville Louisville Kentucky 40503
Karmanos Cancer Center Detroit Michigan 48201
Mercy Research Joplin Joplin Missouri 64804
St. Vincent Frontier Cancer Center Billings Montana 59102
Astera Cancer Care East Brunswick New Jersey 08816
University of Rochester Rochester New York 14642
Stony Brooke Medicine Stony Brook New York 11794
Mercy Research Oklahoma City Oklahoma City Oklahoma 73120
LeHigh Valley Allentown Pennsylvania 18103
Gettysburg Cancer Center Gettysburg Pennsylvania 17325
Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC) Charleston South Carolina 29425
Saint Francis Cancer Center/Bon Secours St. Francis Health System Greenville South Carolina 29607
Avera Cancer Institute Sioux Falls South Dakota 57105
University of Tennessee Medical Center Knoxville Tennessee 37920
Baptist Cancer Center Memphis Tennessee 38120
Texas Oncology-Austin Austin Texas 78745
Texas Oncology-Bedford Bedford Texas 76002
Oncology Consultants, PA Houston Texas 77030
Bon Secours Richmond Richmond Virginia 23114

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03520686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2026 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03520686 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →